Indian pharmaceutical company Cipla has signed an agreement to fully acquire South Africa-based pharmaceutical manufacturer Mirren for R450m ($33.5m).

Cipla entered the deal through its wholly owned South African subsidiary Cipla Medpro, which produces medicines for public and private sectors.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Founded in 1983, Mirren primarily manufactures and distributes over-the-counter (OTC) medicines in South Africa. The firm additionally has operations in Namibia and Botswana.

Cipla expects the acquisition to enhance its market footprint and growth in the OTC market.

The deal will expand the company’s OTC portfolio with the addition of several of the company’s brands such as Broncol cough syrup, Coryx, Tensopyn and Ultimag.

“Cipla aims to take full leverage of this proposed transaction to deliver on its ethos of ‘Caring for Life’, by providing quality, affordable medical products.”

The transaction is set to boost the firm’s manufacturing footprint in South Africa.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cipla South Africa CEO Paul Miller said: “We foresee that this transaction will aid Cipla greatly in future by further improving the range of quality medication that we are able to offer South Africans.

“Furthermore, Cipla aims to take full leverage of this proposed transaction to deliver on its ethos of ‘Caring for Life’, by providing quality, affordable medical products.”

The acquisition is subject to approval by the South African Competition Commission and expected to close before the end of September.

Mirren director Lynton Lomas said: “The acquisition by Cipla will help to ensure that, the continued growth that the Mirren brands have achieved over the past three years will be sustained. The wellbeing of Mirren’s dedicated staff was one of the biggest deciding factors during this process.”

For the fiscal year ended 28 February 2018, Mirren reported turnovers of R152m ($11.3m).